Tango Therapeutics (TNGX) Long-Term Deferred Tax (2020)

Tango Therapeutics (TNGX) recorded quarterly Long-Term Deferred Tax of $31262.0 in Q4 2020.

Tango Therapeutics (TNGX) Long-Term Deferred Tax (2020) Analysis & Trends

Tango Therapeutics' Long-Term Deferred Tax history runs 1 years deep, the most recent figure standing at $31262.0 for Q4 2020.

In Q4 2020, Long-Term Deferred Tax changed N/A year-over-year to $31262.0; the TTM figure through Dec 2020 stood at $31262.0 (changed N/A YoY), while the FY2020 annual figure was $31262.0, changed N/A from the prior year.
Long-Term Deferred Tax was $31262.0 for Q4 2020 at Tango Therapeutics.
In the past five years, Long-Term Deferred Tax ranged from a high of $31262.0 in Q4 2020 to a low of $31262.0 in Q4 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Tango Therapeutics	4.05 Bn	3.67 Bn	-

Historic Data

Download Data

Date	Value
Dec 31, 2020	31,262.00